Edition:
Deutschland

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

13.81USD
3 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.81
Open
$13.71
Day's High
$14.07
Day's Low
$13.61
Volume
250,271
Avg. Vol
279,153
52-wk High
$15.60
52-wk Low
$7.58

About

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium... (more)

Buy/Sell

Sell Hold Buy
4.00 Mean rating from 1 analysts

Overall

Beta: 1.04
Market Cap(Mil.): $1,373.36
Shares Outstanding(Mil.): 101.39
Dividend: --
Yield (%): --

BRIEF-Innoviva Reports First Quarter 2020 Financial Results

* QTRLY EARNINGS PER SHARE $0.59 Source text for Eikon: Further company coverage:

BRIEF-Innoviva Says Co's 2020 Annual Meeting Of Stockholders Will Be Held In Virtual Meeting Format Only

* INNOVIVA INC - CO'S 2020 ANNUAL MEETING OF STOCKHOLDERS WILL BE HELD IN VIRTUAL MEETING FORMAT ONLY Source text for Eikon: Further company coverage:

BRIEF-GSK Says Filing Accepted By EMA For Trelegy Ellipta Use In Adult Patients With Asthma

* GSK FILING ACCEPTED BY EUROPEAN MEDICINES AGENCY FOR TRELEGY ELLIPTA USE IN ADULT PATIENTS WITH ASTHMA

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.36%
Rohstoffe +0.50%
Industrie +0.38%
Konjunktur abhängige Waren & Dienstleistungen +0.29%
Konjunktur unabhängige Waren & Dienstleistungen +0.19%
Finanzindustrie +0.04%
Pharma +0.07%
Technologie +0.14%
Telekommunikation +0.02%